The purpose of this study was to assess the first-line therapeutic performance of imiquimod
5% cream in 17 pregnant women with external anogenital warts. The mean size of total wart …

Objective: To investigate the efficacy and safety of imiquimod 5% cream in the treatment of
anogenital warts in a female population. Methods: In two open-label studies, female patients …

The complete treatment of anogenital warts has not been obtained with any combination of
methods; therefore, new methods are still under investigation. In this study the activity and …

Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are
safe and efficacious to treat anogenital warts. Methods. In two studies 534 women≥ 12 …

Aim The clinical effects of home-therapy with 5% imiquimod cream in the treatment of
cutaneous anogenital warts are evaluated. Methods From March 2000 to January 2002, 57 …

Objective To compare the safety and effectiveness of 5% and 1% imiquimod cream with
vehicle cream in the treatment of external anogenital warts. Design Randomized, double …

This large double-blind, random allocation, vehiclecontrolled trial aimed to investigate the
efficacy and adverse effects of the new immune response modifier, imiquimod 5 per cent …

Treatment of external genital warts with 5% imiquimod cream during pregnancy: a case report
Page 1 CASE REPORT Treatment of external genital warts with 5% imiquimod cream during …

Objectives: Imiquimod 5% cream (Aldara, Meda Farm, Milan, Italy) is largely used for the
treatment of anogenital warts. However, its use during pregnancy is not consolidated with …

Cytodestructive or surgical therapy for patients with anogenital warts is frequently associated
with recurrence. In February 1997, the US Food and Drug Administration approved …